New in the Library (October-November 2024)

Here are the latest items added to the CTN Dissemination Library for October-November 2024 (this post will be updated as new items come in):

Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention. Afshar M, et al. Journal of Addiction Medicine 2024;18(5):511-519. (CTN-0051)

Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. Ross RK, et al. JAMA Network Open 2024;7(10):e2436612.

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV, et al. American Journal of Psychiatry 2021;178(7):660-671. (CTN-0051)

Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. Fishman M, et al. American Journal on Addiction 2021;30(5):433-444. (CTN-0051)

Nonparametric Causal Mediation Analysis for Stochastic Interventional (In)direct Effects. Hejazi NS, et al. Biostatistics 2023;24(3):686-707. (CTN-0051)

Polysubstance Use Before and During Treatment with Medication for Opioid Use Disorder: Prevalence and Association with Treatment Outcomes. Bunting AM, et al. Journal of Substance Abuse Treatment 2022;143:108830. (CTN-0051)

Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Gopaldas M, et al. Psychiatric Services 2023;74(12):1227-1233. (CTN-0051)

Clinical and Psychosocial Outcomes by Sex Among Individuals Prescribed Buprenorphine-Naloxone (BUP-NX) or Extended-Release Naltrexone (XR-NTX) for Opioid Use Disorder. Paschen-Wolff M, et al. American Journal on Addiction 2023;32(6):584-592. (CTN-0051)

Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. Shulman M, et al. Journal of Addiction Medicine 2023;17(5):618-620. (CTN-0051)